HomeREGULATORY
REGULATORY

Harvoni, Sovaldi under Review for Risks of Hypertension, Cerebrovascular Disorder
(Jun.13.2016)

The Pharmaceuticals and Medical Devices Agency (PMDA) said on June 10 that it is reviewing the risks of hypertension and cerebrovascular disorder for hepatitis C drugs Harvoni (ledipasvir + sofosbuvir) and Sovaldi (sofosbuvir), a move that is likely to result ...
(LOG IN FOR FULL STORY)

News Calendar